|Assessment Status||Assessment process complete|
|Indication||For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.|
|Rapid review commissioned||25/09/2013|
|Rapid review completed||24/10/2013|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended.|
|Full pharmacoeconomic assessment commissioned by HSE||05/02/2014|
|NCPE assessment completed||30/06/2014|
|NCPE assessment outcome||Reimbursement Not Recommended.|
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.